The pharmacology of novel oral anticoagulants

Anticoagulant Therapy with the Oral Direct Factor Xa Inhibitors Rivaroxaban, Apixaban and Edoxaban and the Thrombin Inhibitor Dabigatran Etexilate in Patients with Hepatic Impairment

(2013) Jochen Graff et al.   CLINICAL PHARMACOKINETICS

Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors

(2012) Scott Kaatz et al.   AMERICAN JOURNAL OF HEMATOLOGY

Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban

(2012) Raphael Marlu et al.   THROMBOSIS AND HAEMOSTASIS

Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation

(2012) Jeanne Mendell et al.   THROMBOSIS AND HAEMOSTASIS

Preclinical experimental models of drug metabolism and disposition in drug discovery and development

(2012) Donglu Zhang et al.   Acta Pharmaceutica Sinica B

Direct thrombin inhibitors

(2011) Catherine J. Lee et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation

(2011) John W. Eikelboom et al.   CIRCULATION

Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate

(2011) Elise S. Eerenberg et al.   CIRCULATION

Genetic Polymorphisms of OATP Transporters and Their Impact on Intestinal Absorption and Hepatic Disposition of Drugs

(2011) Takeo Nakanishi et al.   Drug Metabolism and Pharmacokinetics

Edoxaban

(2011) A. John Camm et al.   DRUGS

In Vitro and In Vivo P-Glycoprotein Transport Characteristics of Rivaroxaban

(2011) M. J. Gnoth et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Differential propensity for major hemorrhagic events in patients with different types of arterial disease

(2011) S. ACHTERBERG et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial

(2011) K.-H. LIESENFELD et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor

(2011) Pancras C. Wong et al.   JOURNAL OF THROMBOSIS AND THROMBOLYSIS

Drug and dietary interactions of warfarin and novel oral anticoagulants: an update

(2011) Edith Nutescu et al.   JOURNAL OF THROMBOSIS AND THROMBOLYSIS

Apixaban in Patients with Atrial Fibrillation

(2011) Stuart J. Connolly et al.   NEW ENGLAND JOURNAL OF MEDICINE

Apixaban versus Warfarin in Patients with Atrial Fibrillation

(2011) Christopher B. Granger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation

(2011) Manesh R. Patel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pharmacogenetics, Pharmacogenomics, and Individualized Medicine

(2011) Q. Ma et al.   PHARMACOLOGICAL REVIEWS

Novel Oral Anticoagulants and Their Role in Clinical Practice

(2011) Ann K Wittkowsky   PHARMACOTHERAPY

Reversal of anticoagulant effects of edoxaban, an oral, direct factor Xa inhibitor, with haemostatic agents

(2011) Toshio Fukuda et al.   THROMBOSIS AND HAEMOSTASIS

Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor

(2010) Dagmar Kubitza et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Influence of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Oral Dabigatran Etexilate

(2010) Joachim Stangier et al.   CLINICAL PHARMACOKINETICS

Patients with coronary, cerebrovascular or peripheral arterial obstructive disease differ in risk for new vascular events and mortality: the SMART study

(2010) Sefanja Achterberg et al.   EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION

Clinical Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Factor Xa Inhibitor Edoxaban in Healthy Volunteers

(2010) Koichiro Ogata et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Effects of Food on the Pharmacokinetics of Edoxaban, an Oral Direct Factor Xa Inhibitor, in Healthy Volunteers

(2010) Jeanne Mendell et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Membrane transporters in drug development

(2010)   NATURE REVIEWS DRUG DISCOVERY

Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity

(2010) Joachim Stangier et al.   THROMBOSIS AND HAEMOSTASIS

Factor Xa and thrombin as targets for new oral anticoagulants

(2010) Jeffrey I. Weitz   THROMBOSIS RESEARCH

Effects of Drug Transporters on Volume of Distribution

(2009) Anita Grover et al.   AAPS Journal

Impact of OATP transporters on pharmacokinetics

(2009) A Kalliokoski et al.   BRITISH JOURNAL OF PHARMACOLOGY

Pharmacology, Pharmacokinetics, and Pharmacodynamics of Dabigatran Etexilate, an Oral Direct Thrombin Inhibitor

(2009) Joachim Stangier et al.   CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS

Dabigatran versus Warfarin in Patients with Atrial Fibrillation

(2009) Stuart J. Connolly et al.   NEW ENGLAND JOURNAL OF MEDICINE

Apixaban or Enoxaparin for Thromboprophylaxis after Knee Replacement

(2009) Michael Rud Lassen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical Pharmacokinetics and Pharmacodynamics of the Oral Direct Thrombin??Inhibitor Dabigatran Etexilate

(2008) Joachim Stangier   CLINICAL PHARMACOKINETICS

Comparative Pharmacodynamics and Pharmacokinetics of Oral Direct Thrombin and Factor Xa Inhibitors in Development

(2008) Bengt I Eriksson et al.   CLINICAL PHARMACOKINETICS

Apixaban Metabolism and Pharmacokinetics after Oral Administration to Humans

(2008) N. Raghavan et al.   DRUG METABOLISM AND DISPOSITION

Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction

(2008) Roger K. Verbeeck   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Interplay of conjugating enzymes with OATP uptake transporters and ABCC/MRP efflux pumps in the elimination of drugs

(2008) Anne T Nies et al.   Expert Opinion on Drug Metabolism & Toxicology

Efficacy and safety of the oral direct factorXa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study

(2008) et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS